Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Explain how tobacco smoke changes psychotropic metabolism, anticipate toxicity when smoking stops and loss of effect when it resumes, and coordinate smoking cessation with safe dose monitoring across care transitions.
Tobacco-related pharmacokinetic interactions arise when smoke constituents change enzyme activity. CYP1A2 induction increases metabolism of some medicines, so a person who smokes may require a different dose from a similar non-smoker. When smoking stops, enzyme activity falls and the previously tolerated dose can produce higher exposure. The process develops over days and varies between people; it is not a simple immediate subtraction based on the number of cigarettes.
The relevant exposure is combustion smoke. Nicotine patches, gum, lozenges and nicotine-containing e-cigarettes do not reproduce tobacco-smoke enzyme induction. They can treat nicotine withdrawal while clozapine concentrations still rise. This distinction explains why a patient may have little craving yet become increasingly sedated after admission. Ask separately about combustible cigarettes, vaping, nicotine products and any other smoked substances rather than treating all nicotine use as equivalent.
Hospital admission, respiratory illness, a quit attempt or switching to vaping may substantially reduce combustion exposure even if nicotine use continues.
New daytime sleepiness, dizziness, postural symptoms, drooling, confusion or myoclonus after cessation suggests increased exposure requiring review.
Insomnia, suspiciousness, hallucinations or functional decline after resuming cigarettes may reflect lower concentrations as well as other relapse factors.
Pneumonia, fever, ciprofloxacin or fluvoxamine can compound clozapine exposure changes and should be sought explicitly.
There is no universally safe fixed percentage reduction; serious infection, caffeine changes and inhibitors may alter the requirement further, and suspected toxicity needs urgent withholding assessment.
Seek the prescribing team's input and, where available, compare plasma levels before the smoking change and one week later; do not apply this percentage automatically to clozapine.
Treating cravings with nicotine replacement does not protect against the CYP1A2 interaction, but it supports cessation and should be managed alongside the medicine adjustment.
A substantial fall in cigarette consumption can alter exposure before complete abstinence, so waiting for a formal quit date may miss the relevant change.
A patient may compensate for tiredness with more coffee while clozapine exposure is rising, making both symptom interpretation and metabolic effects more complicated.
Asking whether the person expects to smoke when home can reveal an imminent pharmacokinetic change that a generic smoking-status checkbox misses.
Assuming nicotine patches maintain the same clozapine metabolism as combustible cigarettes.
Making identical percentage reductions to every psychotropic on the medication chart.
Waiting for severe toxicity before informing the clozapine team about an abrupt smoke-free admission.
Forgetting to revisit a reduced inpatient dose when cigarette smoking resumes after discharge.
Treating smoking status as a permanent characteristic rather than an exposure that changes with illness and circumstances.
Your practice draft is saved in this browser.
A patient taking clozapine stops cigarettes and uses nicotine patches successfully. Several days later they are much more sedated. Which explanation best fits the relevant pharmacokinetic change?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
An admission is a predictable point of risk. A person may stop suddenly because they are too ill to smoke, have restricted access or enter a smoke-free setting. Infection may independently slow clozapine metabolism, and an antibiotic may add further inhibition. These factors can converge rapidly. At discharge the pattern may reverse as cigarettes resume, particularly if the lower inpatient dose is continued without reassessment. The safest handover records the smoking state on which the current dose is based.
Smoking cessation should remain a positive treatment goal because of its major cardiovascular, respiratory and cancer benefits. Explain the medicine interaction as a reason for planned support and blood tests, not as a reason to avoid quitting. Agree how the person will tell the team about changes, provide cessation treatment and consider practical barriers such as unstable housing or variable access to cigarettes. A collaborative plan is more reliable than asking the person to maintain an exact cigarette count indefinitely.